Secondary Hyperparathyroidism in Chronic Kidney Disease: A Narrative Review Focus on Therapeutic Strategy

Shin-Hwa Tsai,Wei-Chih Kan,Rong-Na Jhen,Yu-Ming Chang,Jsun-Liang Kao,Hsien-Yung Lai,Hung-Hsiang Liou,Chih-Chung Shiao

DOI: https://doi.org/10.1016/j.clinme.2024.100238

2024-08-27

Abstract:Chronic kidney disease (CKD) affects over 10% of the global population. One crucial complication of CKD is secondary hyperparathyroidism (SHPT), marked by elevated parathyroid hormone levels due to hyperphosphatemia, hypocalcemia, and low active vitamin D from impaired renal function. SHPT increases risks of bone deformities, vascular calcification, cardiovascular events, and mortality. This review examines SHPT treatment strategies in CKD patients. First-line treatments include phosphate binders, vitamin D receptor activators, and calcimimetics. When these fail, invasive options like parathyroidectomy (PTX) and thermal ablation are considered. PTX effectively reduces symptoms and improves radiological outcomes, outperforming medical treatment alone in reducing cardiovascular risk and mortality. Thermal ablation techniques, such as microwave, radiofrequency, laser, or high-intensity focused ultrasound, offer less invasive alternatives with promising results. Future research should explore the molecular mechanisms of parathyroid gland hyperplasia and evaluate various treatments' impacts.